-
2 months ago | 
neurologylive.com | Richard Lipton |Isabella Ciccone
WATCH TIME: 3 minutes“In terms of use in clinical practice, we want to treat our patients with the simplest, most effective acute treatments available.
-
2 months ago | 
neurologylive.com | Richard Lipton |Isabella Ciccone
WATCH TIME: 5 minutes "In treatment-refractory patients, the combination product produces excellent 2-hour pain freedom and freedom from the most bothersome symptom, corresponding to an early onset of action but also sustained benefits." AXS-07 (Symbravo; Axsome Therapeutics), a novel agent consisting of meloxicam and rizatriptan, is thought to act by inhibiting calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation, and inhibiting neuroinflammation, pain signal...
-
Nov 27, 2024 | 
headachejournal.onlinelibrary.wiley.com | Richard Lipton |John Kollins |Detlef Albrecht
2hPR 2-h pain relief 5-HT 5-hydroxytryptamine AUC area under the concentration–time curve C max maximum plasma concentration DHE dihydroergotamine PD pharmacodynamics PK pharmacokinetics RCT randomized controlled trial T max time to peak concentration INTRODUCTION Migraine is a common primary headache disorder contributing to significant long-term disability and manifesting in attacks of moderate to severe pulsating unilateral pain with nausea, photophobia, and phonophobia in various...
-
Nov 21, 2024 | 
headachejournal.onlinelibrary.wiley.com | Jessica Ailani |Richard Lipton |Andrew Blumenfeld |Laszlo Mechtler
AE adverse event ALT alanine aminotransferase AST aspartate aminotransferase CGRP calcitonin gene-related peptide CI confidence interval ECG electrocardiogram EM episodic migraine ICHD-3 International Classification of Headache Disorders, third edition PRN as needed QD once daily SD standard deviation TEAE treatment-emergent AE ULN upper limit of normal INTRODUCTION Migraine is a debilitating neurological disease that impacts ~1.1 billion individuals worldwide, with >90% of those individuals...
-
Oct 31, 2024 | 
hmpgloballearningnetwork.com | Richard Lipton
Richard Lipton, MD, Albert Einstein College of Medicine, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine. He also discusses recent advancements in CGRP targeting therapies. Could you please introduce yourself by stating your name, title, organization, and relevant professional experience?
-
Oct 2, 2024 | 
jamanetwork.com | Jessica Lo |John Crawford |Darren M. Lipnicki |Richard Lipton
Key PointsQuestion What is the outcome of a first stroke on cognitive function? Findings In this cohort study of 14 international cohorts of older adults, stroke was associated with a significant acute decline of 0.25 SD in global cognition and a small but significant acceleration in the rate of decline of −0.038 SD per year compared with decline without a previous stroke (−0.049 SD per year).
-
Jul 3, 2024 | 
headachejournal.onlinelibrary.wiley.com | Richard Lipton |Jessica Ailani |Kathleen Mullin |Jelena M Pavlovic
CGRP calcitonin gene–related peptide MOH medication-overuse headache ODT orally disintegrating tablet INTRODUCTION A new class of medication for the acute and/or preventive treatment of migraine, the small molecule calcitonin gene–related peptide (CGRP) receptor antagonists (gepants), was introduced in the United States in 2019 and now includes four agents: rimegepant, ubrogepant, atogepant, and zavegepant.1 In addition to being the only drug class with medicines approved for the acute and...
-
Mar 13, 2024 | 
journals.sagepub.com | Frank Porreca |Edita Navratilova |Joe Hirman |Richard Lipton
Conclusion/InterpretationPublished data evaluating the acute treatment effects of gepant drugs from more than 2595 women and 422 men show significant effects on PF and MBS outcomes in women but the available data do not show significant effects in men. The magnitude of the TE observed was always larger in women than in men. Additionally, the calculated NNTs were higher for men than for women for all gepant studies.
-
Dec 18, 2023 | 
dovepress.com | Richard Lipton |Alexandra Thiry |Beth Morris |Robert Croop
Back to Journals » Journal of Pain Research » Volume 17 Original ResearchHeadache and Facial Pain Authors Lipton RB, Thiry A, Morris BA, Croop R Received 18 December 2023Accepted for publication 8 July 2024 Published 22 July 2024Volume 2024:17 Pages 2431—2441 DOI https://doi.org/10.2147/JPR.S453806Checked for plagiarism YesReview by Single anonymous peer reviewPeer reviewer comments 4 Editor who approved publication: Prof.
-
Dec 12, 2023 | 
lexology.com | Paul F. DePasquale |Lyubomir Georgiev |Richard Lipton |Lily Kang |Ryan Sciortino
In briefIn a November 15 opinion, the US Tax Court held that YA Global (the fund) was engaged in a US trade or business because of the activities of Yorkville Advisers (YA), the fund's US-based asset manager. The YA Global decision could have broad implications for funds, asset managers, and fund investors, especially non-US funds with US investments or US-based asset managers.
